Assembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
November 07, 2019
“We are excited to have Luisa joining the Assembly team. Her clinical training, research experience, and track record in drug development make her ideally suited to lead clinical activities across our HBV and microbiome programs,” said
“I am excited to join Assembly’s leadership team and to help the company pursue potentially curable, finite treatments for the 250 million patients worldwide living with chronic HBV infection,” said Dr. Stamm. “I’m encouraged by the potential for core inhibitors to be a cornerstone of transformative therapeutic regimens and by the data we have shown to date with our portfolio candidates. I also look forward to advancing and expanding our pipeline of microbiome candidates from our differentiated platform for oral live biotherapeutics.”
Dr. Stamm joins Assembly from Gilead where she was a senior member of the HCV and HIV clinical research teams with responsibility for scientific and clinical development activities and overall research strategy. She was Executive Director in the Liver Diseases Therapeutic Area, serving as project team leader of the development of two HCV therapeutics which are now marketed (VOSEVI® and EPCLUSA®1), and Executive Director in the HIV and Emerging Viruses Therapeutic Area, focusing on the development of broadly neutralizing antibodies for HIV cure. In these roles, she supervised Phase 1, 2 and 3 clinical trials, and the filing of initial marketing applications in US, EU,
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of core inhibitors and advancement of our core inhibitors into later stage clinical trials. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as “advances” and “potential.” Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Assembly are more fully detailed under the heading “Risk Factors” in Assembly's Quarterly Report on Form 10-Q for the quarter ended
Source: Assembly Biosciences, Inc.
« back to news page